Ribavirin is ineffective against hepatitis C virus as mono-therapy but is critical in attaining both early virologic response and sustained virologic response when combined with pegylated interferon. Ribavirin has significant dose-limiting toxicities, the most important of which is hemolytic anemia. Taribavirin is a ribavirin pro-drug, which targets the liver and has less incidence of anemia, and it may be a promising alternative to ribavirin in the future.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cld.2009.05.006 | DOI Listing |
Publication Analysis
Top Keywords
virologic response
8
ribavirin
5
ribavirin analogs
4
analogs ribavirin
4
ribavirin ineffective
4
ineffective hepatitis
4
hepatitis virus
4
virus mono-therapy
4
mono-therapy critical
4
critical attaining
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!